Crescent Biopharma (FRA:C68) Total Operating Expense: €149.97 Mil (TTM As of Mar. 2026)


FRA:C68 Crescent Biopharma Inc FRA:C68
10 GF Score
Price €14.60
! 2 Warning Signs
View Full Analysis

What is Crescent Biopharma Total Operating Expense?

Crescent Biopharma FRA:C68 10 Total Operating Expense is €149.97 Mil as of Mar. 2026. GuruFocus rates FRA:C68 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

Crescent Biopharma's Total Operating Expense for the three months ended in Mar. 2026 was €22.29 Mil. Crescent Biopharma's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €149.97 Mil.

Crescent Biopharma Total Operating Expense Related Terms

Crescent Biopharma Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Crescent Biopharma's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Crescent Biopharma Total Operating Expense Chart

Crescent Biopharma Annual Data
Trend Dec24 Dec25
Total Operating Expense
0.00 139.61

Crescent Biopharma Quarterly Data
Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial 13.16 18.23 22.05 87.40 22.29
FRA:C68
10GF Score
Crescent Biopharma Inc FRA:C68
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Crescent Biopharma Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €149.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €149.97 Mil mean?
Crescent Biopharma (FRA:C68) has a Total Operating Expense of €149.97 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Crescent Biopharma and its competitors.
Is Crescent Biopharma's Total Operating Expense too high?
Crescent Biopharma's current Total Operating Expense is €149.97 Mil. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's Total Operating Expense compare to KYTX and ZURA?
Crescent Biopharma's Total Operating Expense of €149.97 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current Total Operating Expense is €149.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (FRA:C68) has a current Total Operating Expense of €149.97 Mil. The current Total Operating Expense is €149.97 Mil. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Crescent Biopharma (FRA:C68), the current Total Operating Expense is €149.97 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Crescent Biopharma Business Description

Other Exchanges CBIO:USA
Address 300 Fifth Avenue, Waltham, MA, USA, 02451
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score

Get the complete analysis for FRA:C68

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€14.60
Price